Bank of America Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock

Insmed (NASDAQ:INSM) had its price objective increased by Bank of America from $211.00 to $213.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price objective would indicate a potential upside of 47.94% from the stock’s previous close.

Several other research firms also recently commented on INSM. Citigroup reissued an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. TD Cowen set a $241.00 price target on Insmed in a report on Thursday, December 18th. Stifel Nicolaus set a $205.00 price objective on Insmed in a report on Thursday, February 19th. Leerink Partners restated an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Finally, Cantor Fitzgerald upped their price target on shares of Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $204.48.

Insmed Trading Up 5.9%

INSM stock opened at $143.98 on Tuesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. Insmed has a 1-year low of $60.40 and a 1-year high of $212.75. The business has a 50 day simple moving average of $151.48 and a two-hundred day simple moving average of $166.27. The company has a market capitalization of $31.03 billion, a price-to-earnings ratio of -22.46 and a beta of 1.13.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same quarter in the previous year, the business earned ($1.32) EPS. The company’s quarterly revenue was up 152.6% on a year-over-year basis. Research analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity

In other Insmed news, CEO William Lewis sold 19,215 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the transaction, the chief executive officer owned 306,891 shares in the company, valued at $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the transaction, the insider directly owned 41,754 shares in the company, valued at approximately $7,315,300.80. This represents a 67.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 189,651 shares of company stock worth $31,533,654 over the last quarter. 3.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC boosted its holdings in Insmed by 8,052.6% during the 4th quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock valued at $21,493,000 after acquiring an additional 121,755 shares during the period. Rockefeller Capital Management L.P. increased its stake in Insmed by 88.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 16,775 shares of the biopharmaceutical company’s stock worth $2,920,000 after purchasing an additional 7,863 shares during the period. Corient Private Wealth LLC increased its stake in Insmed by 34.1% in the fourth quarter. Corient Private Wealth LLC now owns 20,865 shares of the biopharmaceutical company’s stock worth $3,631,000 after purchasing an additional 5,305 shares during the period. Keenan LLC bought a new stake in shares of Insmed during the fourth quarter worth $369,000. Finally, Reflection Asset Management bought a new stake in shares of Insmed during the fourth quarter worth $30,000.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Topline Phase 3b ENCORE results met primary and multiplicity?controlled secondary endpoints and demonstrated improved respiratory symptoms and culture conversion; company plans an sNDA filing in H2 2026 and submission to PMDA, supporting a meaningful label expansion and addressable-market upside. PR Newswire: ENCORE topline results
• Positive Sentiment: Multiple media reports and analysts call the data a clear win that sets up a significant label expansion for ARIKAYCE and point to a larger market opportunity, driving intraday buying. FiercePharma: Label expansion story
• Positive Sentiment: Investor/analyst call transcript provides management commentary on the trial, regulatory timing and commercialization plans — useful for gauging next milestones and potential revenue impact. Seeking Alpha: Call transcript
• Neutral Sentiment: Wells Fargo lowered its price target from $208 to $175 but kept an overweight rating — trims upside but maintains a bullish view on longer-term prospects. Benzinga: Wells Fargo PT change
• Neutral Sentiment: Broad coverage (CNBC, MarketWatch, Investing, Stat, Proactive) amplified the news and helped drive trading volume and the intraday move; market reaction reflects near-term sentiment around the ENCORE readout. CNBC: Market reaction
• Negative Sentiment: Insider activity: the CEO sold about $1.54M of stock recently, which some investors may view as a negative signal despite the positive trial news. American Banking News: Insider selling

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.